The Latest Breaking News from GSK

On Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy.

On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by a progranulin gene mutation (FTD-GRN).

The U.K.’s National Institute for Health and Care Excellence (NICE) is recommending a treatment from a firm jointly owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE) and Shionogi Inc.

The co-CEO model may work with the right “cocktail” combination, but CEOs must be prepared to give the position “everything you possibly have,” she said.

These are the most groundbreaking stories from the new frontier of science and technology right now

Drug companies AstraZeneca, Hikma Pharmaceuticals and GSK were all big risers.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

AnaptysBio, Inc. (NASDAQ:ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.

The outgoing chief executive reshaped the drugmaker, yet scepticism persists over promised revenues

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026.

GSK Chief Executive Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down Dec. 31 after more than eight years at the head of the London-based drugmaker